Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
8.44
-0.23 (-2.65%)
At close: Sep 16, 2025, 4:00 PM EDT
8.36
-0.08 (-0.93%)
After-hours: Sep 16, 2025, 6:02 PM EDT
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $44.06M in the quarter ending May 31, 2025, with 264.34% growth. This brings the company's revenue in the last twelve months to $88.38M, up 41.86% year-over-year. In the fiscal year ending November 30, 2024, Nurix Therapeutics had annual revenue of $54.55M, down -29.15%.
Revenue (ttm)
$88.38M
Revenue Growth
+41.86%
P/S Ratio
7.61
Revenue / Employee
$309,024
Employees
286
Market Cap
645.23M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Nov 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NRIX News
- 4 days ago - Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 4 days ago - Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 5 days ago - Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript - Seeking Alpha
- 6 days ago - Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 19 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors - Seeking Alpha
- 2 months ago - Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 2 months ago - European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia - GlobeNewsWire